<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="mutate">
            <roleset id="Mutate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="physical location where mutation happen// exon, intron //&#x0A;" />
                    <role n="1" descr="mutated entity   // gene //&#x0A;" />
                    <role n="2" descr="changes at molecular level/* always use prepositional phrase */&#x0A;" />
                    <role n="3" descr="changes at phenotype level /* secondary predication */  &#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Muting A1 (EE(437 and 438) to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>The A1 mutation (EE amino acids(437 and 438) to late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>The SOX9 would be significantly mutated to the the two phosphorylation sites PKA (S (64) and S (211) have already been mutated), adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>The model faults can be significantly mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>The mutation A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and FEG-induced mobility change mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>The mutation A1 (EE(437 and 438) to loss of transcriptional repression of the lacZ gene can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>The template fragments are significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate complex activation interaction domains.</text>
                    <arg n="1">complex activation interaction domains</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutated dam target sequences.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>a gene that may have been mutated in late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice was an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>a gene that will be mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>a gene that will mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>gen that is mutated into late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>gen that may have been mutated in the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>gen that was mutated into the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>gene that will be mutated into delayed neuronal cerebro-infant lipofuscinosis (CLN6) variant and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebro-infant lipofuscinosis (CLN6) variant and in nclf mutant mice</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>model faults can be significantly mutated by the sequence the SAP97 RAT sequence, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>model fragrances could be muted for Sa97 RAT sequence, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Analyses of the in vivo transcription of agn-lacZ with a gene that may have been mutated support this conclusion.</text>
                    <arg n="1">a gene</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Analyses of the in vivo transcription of agn-lacZ with a mutated gene that can be mutated support this conclusion.</text>
                    <arg n="1">a mutated gene</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and the sites T235 and T239, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">the sites T235 and T239</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and exon 8, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where acDR DNA of alpha chain cDNA in COS-1 cells.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice, which is the cell mutation.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Muting A1 (EE(437 and 438) in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Muting A1 (EE(437 and 438) to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice (figure 5C, bands 7 and 8).</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>The A1 gene that can be mutated in Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice was a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>The A1 gene that can be mutated into late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice codified a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>The A1 mutation (EE amino acids(437 and 438) in increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>The A1 mutation (EE amino acids(437 and 438) to increasing above the stimulated phosphorylation and change of mobility induced by FEG would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>The A1 mutation (EE(437 and 438)) to abolited increase of EGF and increased phosphorylation and mobility induced by EGF may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>The A1 mutation (EE(437 and 438)) to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>The A1 mutation (EE(437 and 438)) to losing the transcriptional repression of the lacZ gene could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>The A1 mutation (EE(437 and 438)) to losing the transcriptional repression of the lacZ gene has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>The DNA-binding mutant (Stat5aEE-late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice) of Stat5a was mutating by the A1 mutant (EE(437 and 438) of AA.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>The exon 8 can be significantly mutated by the alpha chain cDNA in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>The exon 8 was mutated by the alpha cDNA chain in COS-1 cells, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>The exon 8 would be significantly mutated to the acDR DNA of the alpha chain cDNA in COS-1 cells, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>The mutation A1 (EE(437 and 438) to Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change can mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>The mutation A1 (EE(437 and 438) to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>The mutation A1 (EE(437 and 438) to late infection variations in neuronal lipofuscinosis and nclf mice can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>The the MAP-terminal T235 and T239 A1 mutation (the eh1/GEH sequence) abolition the stimulated increase in GEGF in phosphorylation and preventing the change in mobility introduced by EGF mutating the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in GEGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, parallel positions of residues was identified and mutated.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, we mutated and change parts of residue positions.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate parallel position of waste.</text>
                    <arg n="1">parallel position of waste</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>We have identified rice in exon 5 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when mutated to premature translation abbreviation, severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>exon 5 are observed mutated by rice, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>exon 5 can be mutated by alele, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>exon 8 may have been significantly mutated by alpha-chain cDNA into COS-1 cells, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>exon 8 will be mutated by alpha strand cDNA DNA in cells-1, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>exon 8 will be mutated by alpha-chain cDNA into COS-1 cells, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>gen that can be mutated in Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
